Summaries of health policy coverage from major news organizations
Medi-Cal Adds Newly Approved Viread to its Formulary
Medi-Cal will begin covering the antiretroviral
Viread, recently approved by the FDA, state officials announced Tuesday. The AP/Sacramento Bee reports that the drug, known generically as tenofovir, has been added to
Medi-Cal's formulary of drugs that may be prescribed by doctors without prior approval. Reimbursement is retroactive to Oct. 26, the day the FDA approved Viread. The drug will most likely be prescribed for individuals "who have not responded well" or developed resistance to other therapies. Medi-Cal now covers all 146 FDA-approved HIV/AIDS treatments. The drug is also available to beneficiaries of the
AIDS Drug Assistance Program, which provides medications to people with HIV/AIDS who have annual incomes less than $50,000 (AP/Sacramento Bee, 11/13).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.